Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 11, 2012, Pages 838-849

  Eltink, Charlotte ^a   Lee, Jennifer ^b   Schaddelee, Marloes ^a   Zhang, Wenhui ^b   Kerbusch, Virginie ^f   Meijer, John ^a   Van Marle, Sjoerd ^c   Grunenberg, Nicole ^d,g   Kowalski, Donna ^b   Drogendijk, Ted ^a   Moy, Selina ^b   Iitsuka, Hiromi ^e   Van Gelderen, Marcel ^a   Matsushima, Hiroshi ^e   Sawamoto, Taiji ^e  

^a Astellas Pharma Global Development   (Netherlands)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c PRA Health Sciences   (Netherlands)

^d Charles River Clinical Services Northwest Inc   (United States)

^e ASTELLAS PHARMA INC   (Japan)

^f PharmAspire Consulting   (Netherlands)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

3 adrenoceptor; Mirabegron YM178 pharmacokinetics; Oral controlled absorption system (OCAS); Overactive bladder

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; MIRABEGRON;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; FLATULENCE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OVERACTIVE BLADDER; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE DRUG DOSE; STEADY STATE;

ACETANILIDES; ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BODY WEIGHT; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NETHERLANDS; SEX FACTORS; THIAZOLES; URINARY BLADDER, OVERACTIVE; WASHINGTON; YOUNG ADULT;

EID: 84867345500     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201782     Document Type: Article

References (29)

1. 3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007; 321: 642-647. doi:10.1124/jpet.106.115840 PubMed
2. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P; International Continence Society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009; 28: 287. doi:10.1002/nau.20737 PubMed
3. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med. 1999; 44: 56-66. PubMed (Pubitemid 29228424)
4. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000; 55 (Suppl): 33-46. doi:10.1016/S0090-4295(99) 00492-6 PubMed
5. Garely AD, Burrows LJ. Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother. 2002; 3: 827-833. doi:10.1517/14656566.3.7.827 PubMed (Pubitemid 34752501)
6. 3-adrenoceptors in human detrusor muscle. Urology. 2002; 59 (Suppl 1): 25-29. doi:10.1016/S0090-4295(01)01635-1 PubMed
7. 3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007; 26: 752-756. doi:10.1002/nau.20420 PubMed
8. 3-adrenoceptor agonist, in patients with overactive bladder (OAB). [Abstract 774]. Eur Urol Suppl. 2010; 9: 249. doi:10.1016/S1569-9056(10)60758-0
9. 3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder - results from a European-Australian phase III trial. [Abstract 328]. Eur Urol Suppl. 2011; 10: 278-279. doi:10.1016/S1569-9056(11)60870-1
10. 3-adrenoceptor agonist, in patients with overactive bladder - results from a North American phase III trial. [Abstract 92]. Eur Urol Suppl. 2011; 10: 278. doi:10.1016/S1569-9056(11)60869-5
11. 3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012; 40: 815-824. doi:10.1124/dmd.111.043588 PubMed
12. 3)- adrenoceptor agonist. Xenobiotica. 2012. p. 1-11. doi:10.3109/00498254.2012. 675095 PubMed
13. Astellas Pharma. Betanis tablets Japanese prescriber information. July 2011.
14. Sako K, Nakashima H, Sawada T, Fukui M. Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Pharm Res. 1996; 13: 594-598. doi:10.1023/A:1016006423601 PubMed
15. Teijlingen R, Meijer J, Takusagawa S, Gelderen M, Beld C, Usui T. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 887-888: 102-111. doi:10.1016/j.jchromb.2012.01.018 PubMed
16. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003; 42: 59-98. doi:10.2165/00003088- 200342010-00003 PubMed (Pubitemid 36092258)
17. Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Snijder R, Strabach G, van Marle S, van Gelderen M. Multiple-dose pharmacokinetics of mirabegron, a novel selective beta 3-adrenoceptor agonist, in healthy young and elderly subjects. Br J Clin Pharmacol; In review.
18. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol. 1996; 14: 610-618. PubMed (Pubitemid 26051028)
19. Ernest S, Bello-Reuss E. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int Suppl. 1998; 65: S11-S17. PubMed (Pubitemid 28204559)
20. Koziolek MJ, Riess R, Geiger H, Thévenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int. 2001; 60: 156-166. doi:10.1046/j.1523-1755.2001. 00782.x PubMed (Pubitemid 32587550)
21. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 2002; 72: 474-489. doi:10.1067/mcp.2002.128388 PubMed (Pubitemid 36237718)
22. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007; 82: 87-96. doi:10.1038/sj.clpt.6100226 PubMed (Pubitemid 46944201)
23. Sawamoto T, Lee J, Alak A, Meijer J, Roy M, Zha J, van Gelderen M, Marion AS, Keirns J. Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther. 2011; 89: S21.
24. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002; 41: 329-342. doi:10.2165/ 00003088-200241050-00002 PubMed (Pubitemid 34713088)
25. Paine MF, Ludington SS, Chen ML, Stewart PW, Huang SM, Watkins PB. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos. 2005; 33: 426-433. doi:10.1124/dmd.104.002469 PubMed (Pubitemid 40279944)
26. Lifschitz A, Ballent M, Virkel G, Sallovitz J, Lanusse C. Sex-related differences in the gastrointestinal disposition of ivermectin in the rat: Pglycoprotein involvement and itraconazole modulation. J Pharm Pharmacol. 2006; 58: 1055-1062. doi:10.1211/jpp.58.8.0005 PubMed (Pubitemid 44213637)
27. MacLean C, Moenning U, Reichel A, Fricker G. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos. 2008; 36: 1249-1254. doi:10.1124/dmd.108.020859 PubMed (Pubitemid 351929307)
28. Mariana B, Adrián L, Guillermo V, Juan S, Laura M, Carlos L. Gender-related differences on P-glycoprotein-mediated drug intestinal transport in rats. J Pharm Pharmacol. 2011; 63: 619-626. doi:10.1111/j.2042-7158.2010. 01230.x PubMed
29. 3-adrenoceptor agonist, in rats, monkeys and humans [Poster 1-P1-39]. Presented at the 26th Annual Meeting of The Japanese Society for the Study of Xenobiotics, Hiroshima Japan, 16-18 November 2011.